Timing of HPV vaccine intervals among United States teens with consideration to the current ACIP schedule and the WHO 2-dose schedule

References

• Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2007; 56(Rr-2):1-24; PMID:17380109
   PubMedGoogle Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA Jr, Unger ER; Centers for Disease Control and Prevention (CDC). Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(Rr-05):1-30; PMID:25167164
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Recommendations on the use of quadrivalent human papillomavirus vaccine in males–Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60(50):1705-8; PMID:22189893
   PubMedGoogle Scholar
• Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE; Centers for Disease Control and Prevention (CDC). Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64(11):300-4; PMID:25811679
   PubMed Web of Science ®Google Scholar
• Office of Disease Prevention and Health Promotion, US. Department of Health and Human Services. Healthy People 2020 Topics and Objectives: Sexually Transmitted Diseases. 2014 [ cited 2015 30 March 2015]
   Google Scholar
• Reagan-Steiner S, Yankey D, Jeyarajah J, Elam-Evans LD, Singleton JA, Curtis CR, MacNeil J, Markowitz LE, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years - United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64(29):784-92; PMID:26225476; http://dx.doi.org/10.15585/mmwr.mm6429a3
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol Rec 2014; 89(21):221-36; PMID:24864348
   PubMedGoogle Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89(43):465-91; PMID:25346960
   PubMedGoogle Scholar
• Curtis CR, Dorell C, Yankey D, Jeyarajah J, Chesson H, Saraiya M, Gold R, Dunne EF, Stokley S; Centers for Disease Control and Prevention (CDC). National human papillomavirus vaccination coverage among adolescents aged 13–17 years-National Immunization Survey–teen, United States, 2011. MMWR Surveill Summ 2014; 63 Suppl 2:61-70; PMID:25208260
   PubMedGoogle Scholar
• US. Department of Health and Human Services (DHHS), National Center for Health Statistics. The 2013 National Immunization Survey - Teen. 2014, Hyattsville, MD: Centers for Disease Control and Prevention
   Google Scholar
• Natarajan S, Lipsitz SR, Fitzmaurice GM, Sinha D, Ibrahim JG, Haas J, Gellad W. An extension of the Wilcoxon Rank-Sum test for complex sample survey data. J R Stat Soc Ser C Appl Stat 2012; 61(4):653-64; PMID:23913985; http://dx.doi.org/10.1111/j.1467-9876.2011.01028.x
   PubMed Web of Science ®Google Scholar
• Dorell CG, Stokley S, Yankey D, Markowitz LE. Compliance with recommended dosing intervals for HPV vaccination among females, 13–17 years, National Immunization Survey-Teen, 2008–2009. Vaccine 2012; 30(3):503-5; PMID:22119587; http://dx.doi.org/10.1016/j.vaccine.2011.11.042
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014; 10(5):1155-65; PMID:24576907; http://dx.doi.org/10.4161/hv.28022
   PubMed Web of Science ®Google Scholar
• Dobson SM, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of hpv vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial. JAMA 2013; 309(17):1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
   PubMed Web of Science ®Google Scholar
• Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, González P, Solomon D, Jiménez S, Schiller JT, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103(19):1444-51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
   PubMed Web of Science ®Google Scholar
• Lazcano-Ponce E, Stanley M, Muñoz N, Torres L, Cruz-Valdez A, Salmerón J, Rojas R, Herrero R, Hernández-Ávila M. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014; 32(6):725-32; PMID:24355090; http://dx.doi.org/10.1016/j.vaccine.2013.11.059
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Sand C, Kjaer SK. Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: A nationwide study of 550 000 young girls. Clin Infect Dis 2015; 61(5):676-82; PMID:25944340; http://dx.doi.org/10.1093/cid/civ364
   PubMed Web of Science ®Google Scholar
• Laprise JF, Drolet M, Boily MC, Jit M, Sauvageau C, Franco EL, Lemieux-Mellouki P, Malagón T, Brisson M. Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine 2014; 32(44):5845-53; PMID:25131743; http://dx.doi.org/10.1016/j.vaccine.2014.07.099
   PubMed Web of Science ®Google Scholar
• Jit M, Choi YH, Laprise JF, Boily MC, Drolet M, Brisson M. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine 2014; 32(26):3237-42; PMID:24726246; http://dx.doi.org/10.1016/j.vaccine.2014.03.098
   PubMed Web of Science ®Google Scholar
• Rahman M, Laz TH, McGrath CJ, Berenson AB. Provider recommendation mediates the relationship between parental human papillomavirus (HPV) vaccine awareness and HPV vaccine initiation and completion among 13- to 17-year-old US adolescent children. Clin Pediatr (Phila) 2015; 54(4):371-5; PMID:25238779; http://dx.doi.org/10.1177/0009922814551135
   PubMed Web of Science ®Google Scholar
• Dorell C, Yankey D, Strasser S. Parent-reported reasons for nonreceipt of recommended adolescent vaccinations, national immunization survey: teen, 2009. Clin Pediatr (Phila) 2011; 50(12):1116-24; PMID:21856964; http://dx.doi.org/10.1177/0009922811415104
   PubMed Web of Science ®Google Scholar